AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21500992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetrorelix 0.125 mg/day
Number of subjects: 76
Study 19224658 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate, high-fat (LC) diet
Number of subjects: 91
Study 19224658 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate, high-fibre, low-fat (HC) diet
Number of subjects: 91
Study 19224658 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 91
Study 17342998 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 239
Study 17342998 — intervention group
Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 239
Study 15520052 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 68
Study 15520052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 11165465 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient hospital
Number of subjects: 935
Study 11165465 — intervention group
Group type: COMPARATOR
Intervention: Inpatient hospital
Number of subjects: 935
Study 11165465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory cataract surgery
Number of subjects: 935
Study 9683360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (two daily irradiations of 1.15 Gy up to 80.5 Gy in 7 weeks)
Number of subjects: 325
Study 9683360 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (70 Gy in 7 weeks)
Number of subjects: 325
Study 9683360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (arm 2)
Number of subjects: 325
Study 7884745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 52
Study 7884745 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 52
Study 2462581 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with cat-hair and dander extract (11 patients)
Number of subjects: 22
Study 2462581 — intervention group
Group type: COMPARATOR
Intervention: Placebo (11 patients)
Number of subjects: 22
Study 29845905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime milk snack with 10 g protein (BS10)
Number of subjects: 30
Study 29845905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime milk snack with 30 g protein (BS30)
Number of subjects: 30
Study 29845905 — intervention group
Group type: COMPARATOR
Intervention: Non-energetic placebo (BS0)
Number of subjects: 30
Study 28695567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m tilmanocept (TcTM)
Number of subjects: 52
Study 28695567 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m sulfur colloid (TcSC)
Number of subjects: 52
Study 26149000 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive central hypovolemia and correction of hypovolemia (Group I)
Number of subjects: 40
Study 26149000 — intervention group
Group type: COMPARATOR
Intervention: Hypervolemia alone (Group II)
Number of subjects: 40
Study 23778157 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (600 mg)
Number of subjects: 0
Study 23778157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (200 mg)
Number of subjects: 0
Study 23778157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide (400 mg)
Number of subjects: 0
Study 23778157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19844843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 60
Study 19844843 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 18466213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily)
Number of subjects: 36
Study 18466213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16631435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/d for 5 weeks)
Number of subjects: 20
Study 12851531 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran (60 mg)
Number of subjects: 54
Study 12851531 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (120 IU/kg)
Number of subjects: 54
Study 12851531 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 54
Study 10809270 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic vasospasm risk index
Number of subjects: 283
Study 10809270 — intervention group
Group type: COMPARATOR
Intervention: Thickness of subarachnoid clot
Number of subjects: 283
Study 10809270 — intervention group
Group type: COMPARATOR
Intervention: Early rise in middle cerebral artery mean flow velocity (MCA-MFV)
Number of subjects: 283
Study 10809270 — intervention group
Group type: COMPARATOR
Intervention: Glasgow Coma Scale score <14
Number of subjects: 283
Study 10809270 — intervention group
Group type: COMPARATOR
Intervention: Rupture of anterior cerebral or internal carotid artery aneurysm
Number of subjects: 283
Study 8985764 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nasal application of mupirocin calcium ointment, started on the day before surgery, continued for 5 days, twice daily
Number of subjects: 1796
Study 8985764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mupirocin treatment)
Number of subjects: 1796
Study 8985764 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative nasal application of mupirocin calcium ointment
Number of subjects: 1796
Study 1592526 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation for 14 weeks
Number of subjects: 143
Study 1592526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 4053509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-grip test
Number of subjects: 39
Study 4053509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-pressor test
Number of subjects: 39
Study 4053509 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreceptor stimulation and deactivation by injection of phenylephrine and trinitroglycerine
Number of subjects: 39
Study 4053509 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteration in carotid baroreceptor activity by a neck chamber
Number of subjects: 39
Study 31670070 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (SM)
Number of subjects: 34
Study 31670070 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (verum SM)
Number of subjects: 34
Study 31670070 — intervention group
Group type: COMPARATOR
Intervention: Sham spinal manipulation (sham SM)
Number of subjects: 34
Study 29931179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hydroxocobalamin injections (2000 µg loading dose, 1000 µg at follow-up) for 6 months
Number of subjects: 50
Study 29931179 — intervention group
Group type: COMPARATOR
Intervention: Oral methylcobalamin (1000 µg daily) for 6 months
Number of subjects: 50
Study 29931179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hydroxocobalamin injections
Number of subjects: 50
Study 29931179 — intervention group
Group type: COMPARATOR
Intervention: Oral methylcobalamin
Number of subjects: 50
Study 27136318 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin monotherapy
Number of subjects: 336
Study 27136318 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin combotherapy
Number of subjects: 336
Study 25264972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 grams/d of omega-3
Number of subjects: 138
Study 25264972 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.50 grams/d of omega-3
Number of subjects: 138
Study 25264972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 21925831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 76
Study 21925831 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 76
Study 19363162 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of smoking
Number of subjects: 482
Study 19363162 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of substance use (smoking, alcohol, drug use)
Number of subjects: 482
Study 19363162 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of smoking and drug use
Number of subjects: 482
Study 17346475 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram
Number of subjects: 1932
Study 17346475 — intervention group
Group type: COMPARATOR
Intervention: Standard notes
Number of subjects: 1932
Study 15752943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5 to 5.0 mg/day)
Number of subjects: 40
Study 15752943 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 to 80 mg/day)
Number of subjects: 40
Study 12022434 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma retinol-binding protein (RBP) measurement
Number of subjects: 236
Study 12022434 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 236
Study 12022434 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of plasma RBP by radial immunodiffusion
Number of subjects: 236
Study 10505802 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane with anorganic bovine bone (T)
Number of subjects: 11
Study 10505802 — intervention group
Group type: COMPARATOR
Intervention: Membrane alone (C)
Number of subjects: 11
Study 9183422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 microgram.kg‐1 with bupivacaine 0.25%
Number of subjects: 50
Study 9183422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microgram.kg‐1 with bupivacaine 0.25%
Number of subjects: 50
Study 1758240 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.4 mg/kg
Number of subjects: 64
Study 1758240 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.6 mg/kg
Number of subjects: 64
Study 1758240 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.8 mg/kg
Number of subjects: 64
Study 1758240 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.0 mg/kg
Number of subjects: 64
Study 1758240 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.2 mg/kg
Number of subjects: 64
Study 1758240 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.4 mg/kg
Number of subjects: 64
Study 6278919 — intervention group
Group type: EXPERIMENTAL
Intervention: 475 mg iodized oil by mouth
Number of subjects: 100
Study 6278919 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil (control)
Number of subjects: 100
Study 31509796 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 83
Study 31509796 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 28751063 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal (TAPP) repair
Number of subjects: 134
Study 28751063 — intervention group
Group type: COMPARATOR
Intervention: Open Lichtenstein repair (OLR)
Number of subjects: 134
Study 26755223 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally relevant asthma education intervention
Number of subjects: 40
Study 26755223 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 23994316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral frontal pole (LFP) and anterior insula (AI) activation during voluntary task selection
Number of subjects: 0
Study 23994316 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial prefrontal cortex (MFC) activation during voluntary task selection
Number of subjects: 0
Study 23994316 — intervention group
Group type: EXPERIMENTAL
Intervention: LFP and AI activation in response to irrelevant external stimuli
Number of subjects: 0
Study 22461375 — intervention group
Group type: COMPARATOR
Intervention: Integrated, multi-component, school-based intervention programme including changes in school food environment and physical education classes, educational outreach, behaviour change activities, and a social marketing campaign.
Number of subjects: 4363
Study 22461375 — intervention group
Group type: COMPARATOR
Intervention: Integrated, multi-component, school-based intervention programme
Number of subjects: 4363
Study 20619624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 μg
Number of subjects: 1073
Study 20619624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 μg
Number of subjects: 1073
Study 20619624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 μg
Number of subjects: 1073
Study 20619624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (all doses)
Number of subjects: 1073
Study 20619624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1073
Study 20619624 — intervention group
Group type: COMPARATOR
Intervention: Ciclesonide and Placebo
Number of subjects: 1073
Study 17707045 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiopexy at age 9 months
Number of subjects: 155
Study 17707045 — intervention group
Group type: COMPARATOR
Intervention: Orchiopexy at age 3 years
Number of subjects: 155
Study 15350708 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed endotracheal suction system (closed suction group; N=41)
Number of subjects: 78
Study 15350708 — intervention group
Group type: COMPARATOR
Intervention: Open endotracheal suction system (open suction group; N=37)
Number of subjects: 78
Study 11194245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg)
Number of subjects: 15
Study 11194245 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (2 mg)
Number of subjects: 15
Study 11194245 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.5 mg)
Number of subjects: 15
Study 11194245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9681667 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine without food (30 mg)
Number of subjects: 6
Study 9681667 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine with food (30 mg)
Number of subjects: 6
Study 9681667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8006396 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 MU recombinant interferon alpha 2b (Intron) after steroid withdrawal
Number of subjects: 56
Study 8006396 — intervention group
Group type: COMPARATOR
Intervention: 1.5 MU interferon after placebo withdrawal
Number of subjects: 56
Study 8006396 — intervention group
Group type: COMPARATOR
Intervention: 5 MU interferon after placebo withdrawal
Number of subjects: 56
Study 2573379 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tertatolol (T) once daily for one year
Number of subjects: 230
Study 2573379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the one-month run-in and double-blind period)
Number of subjects: 230
Study 2573379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (T + D)
Number of subjects: 230
Study 798469 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopimozide, 24 mg weekly (Study I)
Number of subjects: 12
Study 798469 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopimozide, daily mean dose of 2.5 mg (Study III)
Number of subjects: 12
Study 798469 — intervention group
Group type: COMPARATOR
Intervention: Clopimozide
Number of subjects: 12
Study 798469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 798469 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopimozide (weekly administration)
Number of subjects: 12
Study 31924591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit
Number of subjects: 47
Study 31924591 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Trainer
Number of subjects: 47
Study 31924591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 47
Study 29260533 — intervention group
Group type: EXPERIMENTAL
Intervention: C+E group (convention + esomeprazole 40 mg/d intravenously for 1 week)
Number of subjects: 45
Study 29260533 — intervention group
Group type: COMPARATOR
Intervention: C group (convention treatment only)
Number of subjects: 45
Study 25149364 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block combined with sciatic nerve block
Number of subjects: 50
Study 25149364 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 50
Study 23147451 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 6
Study 23147451 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and orange juice combined
Number of subjects: 6
Study 21641964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 60
Study 21641964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 60
Study 19614946 — intervention group
Group type: EXPERIMENTAL
Intervention: glulisine + OAD
Number of subjects: 387
Study 19614946 — intervention group
Group type: EXPERIMENTAL
Intervention: glulisine monotherapy
Number of subjects: 387
Study 19614946 — intervention group
Group type: COMPARATOR
Intervention: OAD only
Number of subjects: 387
Study 16791115 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir
Number of subjects: 33
Study 16791115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine-triphosphate
Number of subjects: 33
Study 16791115 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-triphosphate
Number of subjects: 33
Study 16791115 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-RNA
Number of subjects: 33
Study 16791115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin
Number of subjects: 33
Study 16791115 — intervention group
Group type: EXPERIMENTAL
Intervention: BCRP
Number of subjects: 33
Study 14581931 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEPO)
Number of subjects: 0
Study 11413348 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 49
Study 11413348 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 49
Study 15481762 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (FO) 6 g/d
Number of subjects: 6
Study 8513524 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg diluted in 250 ml dextrose 5% administered 30 min before induction of anaesthesia (Group E)
Number of subjects: 50
Study 8513524 — intervention group
Group type: COMPARATOR
Intervention: Dextrose 5% infusion (Group P)
Number of subjects: 50
Study 3106927 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactaid (3,250 neutral lactose units)
Number of subjects: 0
Study 3106927 — intervention group
Group type: EXPERIMENTAL
Intervention: Takamine (6,635 food and chemical codex lactose units)
Number of subjects: 0
Study 3106927 — intervention group
Group type: COMPARATOR
Intervention: Prehydrolyzed milk (standard of reference)
Number of subjects: 0
Study 29653523 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based transdiagnostic REBT universal prevention program
Number of subjects: 338
Study 29653523 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 338
Study 28811749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa Flavanols (900 mg CF)
Number of subjects: 12
Study 28811749 — intervention group
Group type: COMPARATOR
Intervention: Placebo (13 mg CF)
Number of subjects: 12
Study 26142368 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel navigated ultrasound (NUS)
Number of subjects: 44
Study 26142368 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound (CUS)
Number of subjects: 44
Study 23217729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (25mg/day, increasing to 200mg/day by week 6)
Number of subjects: 34
Study 23217729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 21393051 — intervention group
Group type: EXPERIMENTAL
Intervention: Static cyclotorsion compensation (SCC)
Number of subjects: 70
Study 21393051 — intervention group
Group type: COMPARATOR
Intervention: Control group (no static cyclotorsion compensation)
Number of subjects: 70
Study 18458645 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral oophorectomy with no previous hormone therapy use
Number of subjects: 1064
Study 18458645 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral or partial oophorectomy
Number of subjects: 1064
Study 18458645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT) use within 5 years of bilateral oophorectomy
Number of subjects: 1064
Study 18458645 — intervention group
Group type: COMPARATOR
Intervention: No hormone therapy use
Number of subjects: 1064
Study 17176186 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-daughter intervention program for improving rapport
Number of subjects: 0
Study 17176186 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program rated favorably by intervention arm girls and mothers
Number of subjects: 0
Study 17176186 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 15315266 — intervention group
Group type: EXPERIMENTAL
Intervention: SKI306X 200 mg three times daily
Number of subjects: 249
Study 15315266 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg sustained release once daily
Number of subjects: 249
Study 15315266 — intervention group
Group type: EXPERIMENTAL
Intervention: SKI306X
Number of subjects: 249
Study 15315266 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 249
Study 11751710 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1 mg) - acute administration
Number of subjects: 40
Study 11751710 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1 mg) - prolonged administration
Number of subjects: 40
Study 11751710 — intervention group
Group type: COMPARATOR
Intervention: Placebo - acute administration
Number of subjects: 40
Study 11751710 — intervention group
Group type: COMPARATOR
Intervention: Placebo - prolonged administration
Number of subjects: 40
Study 11751710 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (1 mg) - prolonged administration in lean subjects
Number of subjects: 40
Study 9252087 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Number of subjects: 88
Study 9252087 — intervention group
Group type: EXPERIMENTAL
Intervention: colchicine
Number of subjects: 88
Study 9252087 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 88